Abstract
AKT (or protein kinase B) and focal adhesion kinase (FAK) are two important kinases that regulate various cellular functions. Each is overexpressed and/or aberrantly activated in diverse cancers. Several small molecular inhibitors targeting either AKT or FAK are in development or in clinical trials. It is well established that FAK is an upstream regulator of AKT signaling pathway in various cancer cell lines and in xenograft tumor models. However, very recent reports from our laboratory and others demonstrate that AKT can also directly regulate FAK through direct association and serine phosphorylation. This indicates that AKT and FAK may be dual therapeutic targets for pharmacologic intervention in the treatment of primary and metastatic cancer. FAK-AKT interaction is particularly critical for metastatic adhesion. We review recent developments in AKT and FAK signaling in cancer with the particular emphasis on the novel signaling pathways in which FAK is downstream of AKT. We also provide an update on inhibitors targeting AKT or FAK currently in clinical trials.
Keywords: AKT, AKT1, AKT2, cancer, cancer metastasis, cell signaling, differentiation, FAK, FERM, invasion, isoform, migration, proliferation, Src
Anti-Cancer Agents in Medicinal Chemistry
Title: Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Volume: 11 Issue: 10
Author(s): Shouye Wang and Marc D. Basson
Affiliation:
Keywords: AKT, AKT1, AKT2, cancer, cancer metastasis, cell signaling, differentiation, FAK, FERM, invasion, isoform, migration, proliferation, Src
Abstract: AKT (or protein kinase B) and focal adhesion kinase (FAK) are two important kinases that regulate various cellular functions. Each is overexpressed and/or aberrantly activated in diverse cancers. Several small molecular inhibitors targeting either AKT or FAK are in development or in clinical trials. It is well established that FAK is an upstream regulator of AKT signaling pathway in various cancer cell lines and in xenograft tumor models. However, very recent reports from our laboratory and others demonstrate that AKT can also directly regulate FAK through direct association and serine phosphorylation. This indicates that AKT and FAK may be dual therapeutic targets for pharmacologic intervention in the treatment of primary and metastatic cancer. FAK-AKT interaction is particularly critical for metastatic adhesion. We review recent developments in AKT and FAK signaling in cancer with the particular emphasis on the novel signaling pathways in which FAK is downstream of AKT. We also provide an update on inhibitors targeting AKT or FAK currently in clinical trials.
Export Options
About this article
Cite this article as:
Wang Shouye and D. Basson Marc, Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (10) . https://dx.doi.org/10.2174/187152011797927661
DOI https://dx.doi.org/10.2174/187152011797927661 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MDM4 (MDMX) and its Transcript Variants
Current Genomics ADAMTS9-AS2: A Functional Long Non-coding RNA in Tumorigenesis
Current Pharmaceutical Design Inhibitor at the Gates, Inhibitor in the Chamber: Allosteric and Competitive Inhibitors of the Proteasome as Prospective Drugs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Embryonic Stem Cell MicroRNAs: Defining Factors in Induced Pluripotent (iPS) and Cancer (CSC) Stem Cells?
Current Stem Cell Research & Therapy Xanthones from Mangosteen Extracts as Natural Chemopreventive Agents: Potential Anticancer Drugs
Current Molecular Medicine Toxicity and Efficacy of Benzamide Riboside in Cancer Chemotherapy Models
Current Medicinal Chemistry Noscapine and its Analogs as Chemotherapeutic Agent: Current updates
Current Topics in Medicinal Chemistry Medicinal Plants for Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumor Proteasome with Traditional Chinese Medicine
Current Drug Discovery Technologies The Insulin-like Growth Factor-1 Axis and its Potential as a Therapeutic Target in Central Nervous System (CNS) Disorders
Central Nervous System Agents in Medicinal Chemistry Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews Influence of Polymer Molecular Weight on in-vitro Characteristics and Cytotoxicity of Fulvestrant Loaded Nanoparticles
Current Drug Therapy Morphology of C6 Glioma Cells on a Water-Repellent Fractal Alkyl Ketene Dimer Surface
Current Nanoscience Hereditary Papillary Renal Carcinoma Type I
Current Molecular Medicine Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Quantifying Gp96/Grp94 Complexes Preparations for Vaccines: a Key Step Often Inaccurate
Current Medicinal Chemistry Carbon Nanotube: A Versatile Carrier for Various Biomedical Applications
Drug Delivery Letters Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology